[Blood cells and their sensitivity to calcium antagonists in patients with cerebrovascular disorders].
Patients with ischemic-type cerebral dyshematopoiesis have disturbances of blood cell function (their enhanced aggregation and reduction of leucocyte and erythrocyte deformation). Calcium antagonist nifedipine can neutralize these disturbances but it reduces blood cell sensitivity to it. The effectiveness of nifedipine can be increased by giving it in combination with prostacyclin. Blood cell sensitivity to this combination of agents changes insignificantly. It is recommended that nifedipine and medicinal agents which increase blood prostacyclin concentration be used in combination.
Akopov
S E
SE
Martirosian
G R
GR
Tunian
Iu S
IuS
Gabrielian
E S
ES
D000328:Adult; D000368:Aged; D001773:Blood Cells / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D002561:Cerebrovascular Disorders / Q000097:blood* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology
D002121:Calcium Channel Blockers; D011464:Epoprostenol; D009543:Nifedipine
Kletki krovi i ikh chuvstvitel'nost' k antagonistam kal'tsiia u bol'nykh s tserebrovaskuliarnymi zabolevaniiami.